Drug Detail

Information about Trametinib + Palbociclib

Generic Name	Trametinib + Palbociclib
IND
Brand Name (US)
Manufacturer	GlaxoSmithKline
Drug Type
Delivery	Oral
Approval Status
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	MEK Inhibitor + CDK4/6 Inhibitor

Links
Trials of this drug
	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Trial results